Farmas USA

KERX
qué pasa con estas? Las llevas o ya les diste puerta?

Estamos igual XDD. Me alegra leerte.

 

Ahora nos podemos meter en esta:

A startup is pitching a mind-uploading service that is “100 percent fatal”

Nectome will preserve your brain, but you have to be euthanized first

Nectome is a preserve-your-brain-and-upload-it company. Its chemical solution can keep a body intact for hundreds of years, maybe thousands, as a statue of frozen glass. The idea is that someday in the future scientists will scan your bricked brain and turn it into a computer simulation.

The company has won a large federal grant and is collaborating with Edward Boyden, a top neuroscientist at MIT, and its technique just claimed an $80,000 science prize for preserving a pig’s brain so well that every synapse inside it could be seen with an electron microscope.

Following the example of electric-vehicle maker Tesla, it is sizing up demand by inviting prospective customers to join a waiting list for a deposit of $10,000, fully refundable if you change your mind.

In February, they obtained the corpse of an elderly woman and were able to begin preserving her brain just 2.5 hours after her death. It was the first demonstration of their technique, called aldehyde-stabilized cryopreservation, on a human brain.

https://www.technologyreview.com/s/610456/a-startup-is-pitching-a-mind-uploading-service-that-is-100-percent-fatal/

Ni se ya cuantos metesacas llevo con ella ... la estaba mirando hoy ... pero me espero ...

KERX

 

estoy viendo muchos MACD 2h que estan apuntando al rojo inminente y eso son 2 dias bajistas lo menos ... me quedo quieto , aguanto las RGLS compradas hoy pero no compro nada por ahora, me alegro haber hecho caja hoy ( no solo RDUS, unas cuantas mas )

Lo de CELG y REGN es de juzgado de guardia ... ( bueno, y lo de BIIB )

Me voy a esperar a ver como respira todo el viernes ...

 

 

TRIL

Ahora mismo: cutaneous T-cell lymphoma treatment granted FDA orphan designation

 

New guidelines for Type 2 diabetes patients suggests changing a standard for blood-sugar levels that other medical groups still stand by

For most patients, an A1C between 7 and 8 seems to be the right spot where you maximize benefit and minimize burden

the burdens of striving for a lower number include a greater risk of low blood sugar, which can cause fainting. Patients taking medication to reach a lower A1C level may face side effects and weight gain. Studies have found that the more aggressive treatment of diabetes didn’t reduce deaths or complications, including heart attacks or strokes

https://www.wsj.com/articles/diabetes-debate-leaves-little-consensus-1520864350?mod=searchresults&page=1&pos=2

TEVA

De Twitter. En la Cowen Healthcare: "We're focusing on executing the reestructuring plan,executing the launch of special products & trying to fix the US generic business. Its gonna be a busy couple of years (...)hopefully getting the CO in the right shape(...) back on growth in a couple of years

BLCM

PR

Bellicum Submits Response to FDA Clinical Hold on BPX-501 Trials

Recruitment Complete in BPX-501 E.U. Registration Trial

Positive BPX-501 Interim Results Reported in AML and Primary Immunodeficiencies: interim clinical data showing its BPX-501 T cells appear to contribute to a durable anti-leukemic effect in older patients with acute myeloid leukemia.

Robust BPX-601 GoCAR-T™ Cell Expansion Observed Following Rimiducid Administration :  Phase 1 study patients with nonresectable pancreatic cancer

Collaborator CD19 CAR-T Trial Initiated: phase 1 pediatric ALL clinical trial to assess the impact of CaspaCIDe in managing the acute toxicities of CAR-T therapy.

Completed Buildout of In-House Manufacturing and Vector Production Facility

ANTICIPATED 2018 MILESTONES

•Report updated data from the BP-004 study of BPX-501

•Initiate pivotal clinical trials of BPX-501 in adult AML and in either pediatric AML or PIDs, pending regulatory clearances

•Report initial results from the BPX-601 clinical trial, and expand the trial to include additional PSCA-expressing cancers

•Present initial findings from the BPX-701 clinical trial at upcoming medical meetings

Bellicum ended the year on December 31, 2017 with cash, restricted cash and investments totaling $106.5 million, compared to $113.4 million at December 31, 2016. In the fourth quarter of 2017, the Company paid off its Hercules Capital debt facility with a $35.0 million loan from Oxford Finance. The new loan provided approximately $2.1 million in additional liquidity, interest-only payments until February 1, 2020 and a lower interest rate. Based on current operating plans, Bellicum expects that current cash resources will be sufficient to meet operating requirements through the first quarter of 2019.

 

https://www.sec.gov/Archives/edgar/data/1358403/000135840318000039/exh991-earningsrelease.htm

XBI

ese hombre colgado no auguraba nada bueno ...

pues asi anda la cosa, la cuña ascendente ya rota

KERX

A la espera de ver como se mueve ... MACD diario a punto de irse a bearish

ACAD 

tope en segundo retroceso fibo ... se acabo el gato muerto de marras ... ahora vamos a ver hasta donde baja ...